2000000395-4

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

IPOS

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 471/14, A61K 31/50 // (C07D 471/14, 249:00, 237:00, 221:00)

A1

(11) International Publication Number: WO 99/06404

(43) International Publication Date: 11 February 1999 (11.02.99)

(21) International Application Number: PCT/EP98/04340

(22) International Filing Date: 13 July 1998 (13.07.98)

(30) Priority Data:
9701670 29 July 1997 (29.07.97) ES

(71) Applicant *(for all designated States except US)*: ALMIRALL PRODESFARMA S.A. [ES/ES]; General Mitre, 151, E-08022 Barcelona (ES).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GRACIA FERRER, Jordi [ES/ES]; Plaza de las Navas, 5, 4°-2ª, E-08004 Barcelona (ES). CRESPO CRESPO, M. Isabel [ES/ES]; Calle Comte d'Urgell, 259, 6°-3ª, E-08036 Barcelona (ES). VEGA NOVEROLA, Armando [ES/ES]; Traversera de Dalt, 62-64, 7°-3ª, E-08024 Barcelona (ES). FERNANDEZ GARCIA, Andrés [ES/ES]; Calle Josep Irla i Bosch, 6, 5°-1ª, E-08034 Barcelona (ES).

(74) Agent: GOLDIN, Douglas, Michael; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published
With international search report.

1 PD IPC: C07D471/14
1 appln IPER 23/2/99
4 Invs. (Look for symbols)

(54) Title: 1,2,4-TRIAZOLO[4,3-B]PYRIDO[3,2-D]PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

(57) Abstract

Heterocyclic compounds of formula (I), wherein R^1 represents a hydrogen atom or a $-(CH_2)_m-Y$ group, wherein m is an integer from 0 to 4 and Y represents an alkyl, haloalkyl, alkoxy, alkoxycarbonyl, C_3–C_7 cycloalkyl, norbornyl or phenylalkenyl group, or an aromatic group which aromatic group Y may optionally be substituted by one or more halogen atoms; R^2 represents an aromatic group which aromatic group may optionally be substituted by one or more halogen atoms or alkyl, alkoxy, C_3–C_6 cycloalkoxy, methylenedioxy, nitro, dialkylamino or trifluoromethyl groups; and R^3 represents a hydrogen or halogen atom or an alkyl group, and pharmaceutically acceptable salts thereof, processes for preparing the same. The compounds are phosphodiesterase 4 inhibitors.



(I)